ArticleBiochemistry and biophysics reports2026
Emodin inhibits breast tumorigenesis in the comorbidity of hyperlipidemia and associated with IL-17 suppression.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study explored the interaction between breast cancer and the hyperlipidemia microenvironment, and assessed the anti-tumorigenic effects of the natural compound Emodin. Methods: The human cancer atlas and gene expression databases were used to identify links between breast cancer and hyperlipidemia. Oxidized LDL (oxLDL) stimulation Results: Lipid metabolism mediators CD36 and IL-17 activation were associated with breast cancer development. Bioinformatics identified IL-17 priming cytokines, and Conclusion: Emodin effectively reduced tumorigenesis in HFD mice, accompanied with inhibited IL-17 expression and suppressed macrophage infiltration. This result provided evidence for the pro-tumorigenic role of hyperlipidemia in breast cancer development, and support the natural compound Emodin as a promising anti-tumor agent with targeting IL-17 signaling molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.